LRRTM3 Antibody
| Code | Size | Price |
|---|
| PSI-6171-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6171-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LRRTM3 Antibody: Leucine-rich repeat transmembrane neuronal protein 3
Application Note:
LRRTM3 antibody can be used for detection of LRRTM3 by Western blot at 0.5 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
LRRTM3 Antibody: The Leucine-rich repeat transmembrane neuronal proteins (LRRTMs) are differentially expressed in the nervous system and were recently found to instruct presynaptic and mediate postsynaptic glutamatergic differentiation, with LRRTM1 and LRRTM2 most potent at inducing presynaptic differentiation. Recent evidence suggests that LRRTM3 promotes the processing of amyloid-precursor protein (APP) by the beta-secretase BACE, leading to the proteolytic production of the Abeta42 peptide that is the main component of amyloid plaques. Furthermore, LRRTM3 maps to a region of chromosome 10 linked to both late-onset Alzheimer's disease (AD) and elevated plasma Abeta42 levels, suggesting that LRRTM3 is a functional and positional candidate gene for AD.
Background References:
- Lauren J, Airaksinen MS, Saarma M, et al. A novel gene family encoding leucine-rich repeat transmembrane protein differentially expressed in the nervous system. Genomics 2003; 81:411-21.
- Linhoff MW, Lauren J, Cassidy RM, et al. An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. Neuron 2009; 61:734-49.
- Siddiqui TJ, Pancaroglu R, Kang Y, et al. LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development. J. Neurosci. 2010; 30:7495-506.
- Majercak J, Ray WJ, Espeseth A, et al. LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006; 47:17967-72.
Buffer:
LRRTM3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
LRRTM3 antibody was raised against a 18 amino acid synthetic peptide near the carboxy terminus of human LRRTM3.
The immunogen is located within the last 50 amino acids of LRRTM3.
The immunogen is located within the last 50 amino acids of LRRTM3.
NCBI Gene ID #:
347731
NCBI Official Name:
leucine rich repeat transmembrane neuronal 3
NCBI Official Symbol:
LRRTM3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_821079
Protein GI Number:
109809759
Purification:
LRRTM3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience
SPECIFICITY:
At least two isoforms of LRRTM3 are known to exist; this antibody will only detect the larger isoform.
Swissprot #:
Q86VH5
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LRRTM3 Peptide | PSI-6171P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|